FIELD: medicine; neurology.
SUBSTANCE: group of inventions relates to the field of medicine, namely to neurology; it is intended for the treatment of multiple sclerosis. A method for the treatment of multiple sclerosis includes a) administration of ofatumumab to a patient according to a loading dose scheme at a dose of 20 mg of ofatumumab during 0, 1st, and 2nd weeks; and b) administration of ofatumumab to a patient according to a supporting dose scheme at a dose of 20 mg of ofatumumab, starting from the fourth week of the dosing scheme, and then continuing every four weeks. In another embodiment, the use of a method for administration of ofatumumab for the treatment of multiple sclerosis is provided.
EFFECT: use of the group of inventions allows for increase in the efficiency of treatment of multiple sclerosis with a high safety profile.
15 cl, 5 dwg, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| REGIMEN AND METHODS FOR MULTIPLE SCLEROSIS TREATMENT USING OFATUMUMAB | 2017 |
|
RU2749951C2 |
| METHOD OF TREATING MULTIPLE SCLEROSIS | 2005 |
|
RU2384345C2 |
| METHOD FOR TREATING MULTIPLE SCLEROSIS | 2015 |
|
RU2757961C2 |
| SUBSTANCES AND METHODS OF TREATING MULTIPLE SCLEROSIS MEDIATED BY B CELLS | 2009 |
|
RU2522251C2 |
| PEPTIDE FROM THE COMPOSITION OF THE IMMUNOGLOBULIN HUMAN HEAVY CHAIN, SUITABLE FOR TREATMENT OF MULTIPLE SCLEROSIS | 2016 |
|
RU2646817C1 |
| ANTIBODIES TO CD40 FOR USE IN THE TREATMENT OF SJOGREN'S SYNDROME | 2018 |
|
RU2790558C2 |
| APPLICATION OF SINGLE DOSE OF CD20-SPECIFIC BINDING MOLECULES | 2006 |
|
RU2421242C2 |
| USING ANTIBODIES FOR TREATING AUTOIMMUNE DISEASES IN PATIENT WITH INADEQUATE RESPONSE TO TNF-ALPHA INHIBITOR | 2008 |
|
RU2489166C2 |
| COMBINATION OF ANTI-EDb FIBRONECTIN ANTIBODY-IL-2 FUSION PROTEIN, AND MOLECULE BINDING TO B-CELLS, B-CELL PROGENITORS AND/OR THEIR CANCEROUS COUNTERPART | 2008 |
|
RU2484845C2 |
| METHOD AND COMPOSITION FOR REDUCTION OF MICROMOLECULE AGGREGATION UNDER PHYSIOLOGICAL CONDITIONS | 2009 |
|
RU2563823C2 |
